Compare iShares 10 20 Year Treasury Bond ETF (TLH) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 10 20 Year Treasury Bond ETF vs Viatris Inc — how do they compare? iShares 10 20 Year Treasury Bond ETF trades at $96.63, while Viatris Inc trades at $16.22 (market cap $18.69B). The key difference: Viatris Inc pays a 2.95% dividend while iShares 10 20 Year Treasury Bond ETF pays none, and Viatris Inc is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| TLH | VTRS | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $105.36 | $17.86 |
52-Week Low | $96.39 | $9.49 |
Market Cap | — | $18.69B |
Enterprise Value | — | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TLH trades at $96.86, up 0.49% today, but technical indicators signal a bearish trend with moving averages and ADX pointing downward. The stock lacks disclosed financial ratios, limiting fundamental clarity. Recent corporate actions include consistent dividend payments, with the latest being $0.38 per share scheduled for August 2026. Market sentiment is influenced by broader economic factors like rising Treasury yields and oil price volatility, as highlighted in recent financial news.
The outlook for TLH is cautious due to weak technical momentum and absent key financial metrics, though dividend stability offers some support. Risks include macroeconomic pressures from potential Fed rate hikes and inflation. Investors should seek updated earnings reports for fundamental reassessment, as current data gaps hinder a full evaluation of growth prospects or valuation attractiveness.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
